{"id":7237,"date":"2024-07-09T10:17:00","date_gmt":"2024-07-09T14:17:00","guid":{"rendered":"https:\/\/new.www.purdue.edu\/newsroom\/?p=7237"},"modified":"2024-08-20T11:05:47","modified_gmt":"2024-08-20T15:05:47","slug":"biotech-company-eradivir-is-developing-lead-drug-ev25-to-treat-influenza","status":"publish","type":"post","link":"https:\/\/www.purdue.edu\/newsroom\/2024\/Q3\/biotech-company-eradivir-is-developing-lead-drug-ev25-to-treat-influenza","title":{"rendered":"Biotech company Eradivir is developing lead drug EV25 to treat influenza"},"content":{"rendered":"

WEST LAFAYETTE, Ind. —<\/p> \n

Eradivir<\/a>, a preclinical biotech company, leverages small molecule targeting technology developed in Philip Low\u2019s<\/a> lab at Purdue University to focus on a platform of immunotherapies for viral infections like influenza and other diseases.<\/p>\n<\/div>\n\n\n

CEO Martin Low said Eradivir\u2019s lead drug EV25 treats influenza, a disease that affects up to 40 million Americans, kills between 10,000 and 50,000, and hospitalizes 150,000 to 750,000 annually.<\/p>\n\n\n\n

\u201cEV25 relies on a U.S. Food and Drug Administration-approved drug as a basis to deliver an attached immunogenic payload containing haptens, specifically to the surface of virus and virus-infected cells,\u201d Martin Low (rhymes with \u201cnow\u201d) said. \u201cAs a result, EV25 both inhibits viral reproduction and kills the flu virus and infected cells.\u201d<\/p>\n\n\n\n

Martin Low said EV25 has demonstrated several advantages over current influenza drugs.<\/p>\n\n\n\n

\u201cIt promotes a quicker recovery even after delaying treatment well beyond the standard 48 hours from the appearance of symptoms,\u201d he said. \u201cIt also reduces both the risk of drug resistance and the number of doses required to only one.\u201d<\/p>\n\n\n\n

Developmental steps<\/h2>\n\n\n\n

Eradivir has successfully completed preclinical studies required by regulatory agencies to dose EV25 in humans. <\/p>\n\n\n\n

\u201cA Phase I study, designed to indicate the safety of EV25 in healthy volunteers, is scheduled to begin in Antwerp, Belgium, at the end of the year,\u201d Martin Low said. \u201cAlso planned for 2025 are two Phase II studies that will confirm safety and indicate the efficacy of EV25.\u201d<\/p>\n\n\n\n

Martin Low said because Eradivir\u2019s overall immunological technology platform has the potential to treat multiple diseases, the company is also conducting studies on other molecules to treat dengue and RSV, or respiratory syncytial virus.<\/p>\n\n\n\n

\u201cWe have seen some early success and hope to demonstrate proof of concept for one of these molecules by the end of the year,\u201d he said. <\/p>\n\n\n\n

Eradivir leadership<\/h2>\n\n\n\n

Eradivir\u2019s team has been very successful in developing small molecule therapies in cancer, autoimmune diseases and infectious diseases. Its board members include Philip Low and Raymond Schinazi, who have worked on several drugs that have been approved for the market. <\/p>\n\n\n\n

\u201cWe have built a team that understands viruses and how to develop small molecules. Many of us have worked together in the past and know how to get things done,\u201d Martin Low said.<\/p>\n\n\n\n

Eradivir\u2019s Purdue University connections<\/h2>\n\n\n\n

Philip Low is Purdue\u2019s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry in the College of Science<\/a>. He also is on the faculty of the Purdue Institute for Drug Discovery<\/a> and the Purdue Institute for Cancer Research<\/a>. He has started seven successful companies based on his research, and three of his drugs have been approved by the FDA.<\/p>\n\n\n\n

\u201cIt is our goal to continue our discovery work in these areas at Purdue University,\u201d Martin Low said. \u201cOur investors share this vision and have to date contributed over $18 million in financing.\u201d<\/p>\n\n\n\n

Philip Low disclosed the immunological technology innovations to the Purdue Innovates Office of Technology Commercialization<\/a>, which has applied for a patent to protect the intellectual property. OTC licensed the innovations to Eradivir for further development and commercialization. <\/p>\n\n\n\n

About Eradivir<\/h2>\n\n\n\n

Eradivir\u2019s goal is to focus the power of the immune system to treat disease. Its small-molecule, bispecific immunotherapy tethers a patient\u2019s immune cells specifically to a diseased cell facilitating its rapid and selective destruction. Its first drug to go into humans, EV25, is directed against influenza. <\/p>\n\n\n\n

About Purdue Innovates Office of Technology Commercialization<\/h2>\n\n\n\n

The Purdue Innovates Office of Technology Commercialization<\/a> operates one of the most comprehensive technology transfer programs among leading research universities in the U.S. Services provided by this office support the economic development initiatives of Purdue University and benefit the university\u2019s academic activities through commercializing, licensing and protecting Purdue intellectual property. In fiscal year 2023, the office reported 150 deals finalized with 203 technologies signed, 400 disclosures received and 218 issued U.S. patents. The office is managed by the Purdue Research Foundation, which received the 2019 Innovation & Economic Prosperity Universities Award for Place from the Association of Public and Land-grant Universities. In 2020, IPWatchdog Institute ranked Purdue third nationally in startup creation and in the top 20 for patents. The Purdue Research Foundation is a private, nonprofit foundation created to advance the mission of Purdue University. Contact otcip@prf.org<\/a> for more information.<\/p>\n","protected":false},"excerpt":{"rendered":"

WEST LAFAYETTE, Ind. — Eradivir, a preclinical biotech company, leverages small molecule targeting technology developed in Philip Low\u2019s lab at Purdue University to focus on a platform of immunotherapies for viral infections like influenza and other diseases. CEO Martin Low said Eradivir\u2019s<\/p>\n","protected":false},"author":7,"featured_media":7238,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[19,316],"tags":[],"department":[24],"source":[35],"purdue_today_topic":[],"coauthors":[44],"class_list":["post-7237","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general","category-prf","department-research-foundation","source-purdue-research-foundation"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts\/7237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/comments?post=7237"}],"version-history":[{"count":2,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts\/7237\/revisions"}],"predecessor-version":[{"id":7241,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/posts\/7237\/revisions\/7241"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/media\/7238"}],"wp:attachment":[{"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/media?parent=7237"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/categories?post=7237"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/tags?post=7237"},{"taxonomy":"department","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/department?post=7237"},{"taxonomy":"source","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/source?post=7237"},{"taxonomy":"purdue_today_topic","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/purdue_today_topic?post=7237"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.purdue.edu\/newsroom\/wp-json\/wp\/v2\/coauthors?post=7237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}